Webinar: Updates in Primary CNS Lymphoma

Listen

Lymphoma Australia invites you to our next free educational webinar tailored to patients, families, and carers of those affected by Primary Central Nervous System (CNS) Lymphoma.

This session will explore key updates in Primary CNS Lymphoma, including current and future treatment options.

Event Details

Date: Wednesday 22nd October 2025
Time: 4:00pm to 5:30pm (AEST)
3:00pm to 4:30pm (AEDT)
2:30pm to 4:00pm (ACST)
1:00pm to 2:30pm (AWST)
Location: Online via Zoom – Link sent on registration
Cost: Free – Registration required

Guest Presenter

A/Professor Matthew Ku
A/Prof Matthew Ku is a clinical and laboratory haematologist and lymphoma clinician researcher. His academic career is significant due to his involvement in both lymphoma clinical research and teaching, while working in a full time clinical capacity. His leadership roles include co-Deputy Director of SVHM Clinical Haematology, Aggressive Lymphoma tumour stream Lead, SVHM Immune Effector Cell (IEC) Steering Committee Chair, and SVHM Grand Round Committee Chair.

He is a Principal Investigator of 32 clinical trials in lymphoma, with collaborations with the ALLG, ALA and St Vincent’s Institute (SVI). He is on global scientific advisory boards. He established the first clinical trial collaborations in lymphoma between the ALLG and Nordic Lymphoma Group (NLG) as well as the ALLG and the Italian FIL group. He is currently the coordinating principal investigator of 2 multicentre international investigator initiated trials in lymphoma with associated translational and correlative studies. To date, he has published more than 50 peer reviewed papers and over 70 abstracts presented at international scientific conferences. He has been an invited speaker on lymphoma at multiple meetings and conferences.

A/Prof Ku’s ultimate goal is to establish strong national and international collaborations in lymphoma research that will result in improved evidence-based patient management, leading to better outcomes and prognosis.

Spaces are limited so register now to secure your place.

For more info email nurse@lymphoma.org.au or call the Nurse Support Line on 1800 953 081.

There is limited availability for this event, so secure your spot quickly.

This event has already taken place.

Details

Date: Wednesday 22nd of October 2025

Time: 4:00pm AEDT - 5:30pm AEDT

For more info email: nurse@lymphoma.org.au or phone 1800 953 081.

Support and information

Patient Online Forum

Find Out More

Order Our Resources

Find Out More

Fundraise for us

Get started

Contact Lymphoma Australia Today!

Patient Support Hotline

General Enquiries

Please note: Lymphoma Australia staff are only able to reply to emails sent in English language.

For people living in Australia, we can offer a phone translation service. Have your nurse or English speaking relative call us to arrange this.

Useful Definitions

Refractory: This means the lymphoma does not get better with treatment. The treatment didn’t work as hoped.
Relapsed: This means the lymphoma came back after being gone for a while after treatment.
2nd line treatment: This is the second treatment you get if the first one didn’t work (refractory) or if the lymphoma comes back (relapse).
3rd line treatment: This is the third treatment you get if the second one didn’t work or the lymphoma comes back again.
Approved: Available in Australia and listed by the Therapeutics Goods Administration (TGA).
Funded: Costs are covered for Australian citizens. This means if you have a Medicare card, you shouldn’t have to pay for the treatment.[WO7]

You need healthy T-cells to make CAR T-cells. For this reason, CAR T-cell therapy cannot be used if you have a T-cell lymphoma – yet.

For more information on CAR T-cells and T-cell lymphoma click here.

Special Note: Although your T-cells are removed from your blood for CAR T-cell therapy, most of our T-cells live outside of our blood – in our lymph nodes, thymus, spleen and other organs.